342 related articles for article (PubMed ID: 8097114)
1. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
[TBL] [Abstract][Full Text] [Related]
2. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
Nordström AL; Farde L
J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
[TBL] [Abstract][Full Text] [Related]
3. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
4. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
5. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
[TBL] [Abstract][Full Text] [Related]
6. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
9. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
10. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
[TBL] [Abstract][Full Text] [Related]
12. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
Nyberg S; Farde L; Halldin C
Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
[TBL] [Abstract][Full Text] [Related]
13. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
Farde L; von Bahr C
Acta Psychiatr Scand Suppl; 1990; 358():67-71. PubMed ID: 1978494
[TBL] [Abstract][Full Text] [Related]
14. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
15. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
16. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
[TBL] [Abstract][Full Text] [Related]
17. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
Wiesel FA; Farde L; Nordström AL; Sedvall G
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
[TBL] [Abstract][Full Text] [Related]
18. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
[TBL] [Abstract][Full Text] [Related]
19. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.
Nordström AL; Farde L; Nyberg S; Karlsson P; Halldin C; Sedvall G
Am J Psychiatry; 1995 Oct; 152(10):1444-9. PubMed ID: 7573582
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
